
Pharmacally
Lung Cancer
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Lung Cancer
Health TidingsLilly Reports Promising Results for Olomorasib in Lung CancerEli Lilly presented updated ESMO 2026 data showing antitumour activity with investigational olomorasib in first-line KRAS G12C-mutant non-small cell lung cancer.Fact-Checked
Clinical TrialsRoche’s Divarasib Improves Survival in KRAS G12C Lung CancerRoche’s Phase III KRASCENDO 1 trial showed improved overall survival, progression-free survival and tumour response with investigational divarasib compared with sotorasib or adagrasib in previously treated KRAS G12C-mutated…Fact-Checked
Clinical TrialsAstraZeneca and HUTCHMED Report Positive SAFFRON Phase III Results in MET-Driven Lung CancerSAFFRON Phase III showed significant progression-free and overall survival benefits with savolitinib plus osimertinib in MET-driven EGFR-mutated NSCLC. Written By…Fact-Checked
Mergers & AcquisitionsAstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expand EGFR-Mutated Lung Cancer PortfolioAstraZeneca has licensed global rights to Zegfrovy (sunvozertinib) from Dizal in a deal valued at up to $1.5 billion.Fact-Checked
Health TidingsMHRA Validates Eisai’s Taletrectinib for ROS1-Positive Lung CancerEisai has reached another regulatory milestone for taletrectinib as the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) validated its Marketing Authorisation Application for adults with advanced ROS1-positive…Fact-Checked
Health TidingsLantern Reports Durable LP-300 Responses in EGFR L858R Lung CancerLantern Pharma announced updated Phase 2 HARMONIC trial results demonstrating prolonged progression-free survival, durable responses, and a favorable safety profile for LP-300 in combination with carboplatin and pemetrexed…Fact-Checked
Health TidingsFDA Takes Up Zipalertinib Application for Lung CancerThe FDA has accepted for review the NDA for zipalertinib in patients with EGFR exon 20 insertion–mutated NSCLC following platinum-based chemotherapy.Fact-Checked
New Drug ApprovalMHRA Approves Sevabertinib for HER2+ Lung CancerSevabertinib (Hyrnuo) receives MHRA approval for adults with advanced HER2-mutant Non-small cell lung cancer after prior therapy, showing a 71% response rate in clinical studies.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.